A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BGB-45035 Versus Placebo in Patients With Moderate to Severe Active Rheumatoid Arthritis
Latest Information Update: 20 Mar 2026
At a glance
- Drugs BGB 45035 (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 26 Feb 2026 According to BeOne Medicines media release, Phase 1/2 trial data readout for the treatment of adult patients with rheumatoid arthritis is expected in 2H 2026.
- 06 Nov 2025 According to BeOne Medicines media release, the company achieved first patient enrollment in this study.
- 16 Sep 2025 Status changed from not yet recruiting to recruiting.